title: Clinical efficacy of albendazole emulsion in treatment of 212 cases of liver cystic hydatidosis.
abstract: OBJECTIVE
  To evaluate the clinical efficacy of a new formulation of albendazole emulsion (AbzE) in cases of liver cystic hydatidosis.
  
  
  METHODS
  Two regimens of AbzE (10 mg.kg(-1).d(-1) and 12.5 mg.kg(-1).d(-1)) were given to 212 patients with liver cystic hydatidosis in courses ranging from 3 months to more than one year. Assessment of drug efficacy was essentially based on imaging signs with ultrasonography as the main tool. Assessments were performed at the end of different courses and in the follow-up study of 1 - 4 years after the cessation of therapy.
  
  
  RESULTS
  At the end of therapeutic courses, the overall cure rate of the 212 cases was 74.5%, with a 99.1% effective rate. In the follow-up study, the cure rate was 83.1%, effective rate was 89.3%, ineffective rate was 0.6%, and recurrence rate was 10.2%. The highest cure rate was observed in cases receiving AbzE 12.5 mg.kg(-1).d(-1) for 9 months. Retreatment of recurrent cases with AbzE obtained satisfactory results.
  
  
  CONCLUSIONS
  AbzE surpassed other currently used antihydatidosis drugs or formulations with its promising efficacy and mild side effects, and could be recommended as a drug of choice in the treatment of cystic hydatidosis.
authors.affiliation: Xinjiang Institute for Endemic Diseases Control and Research, Urumqi 830002, China. jchai@xj.cninfo.net
authors.forename: Junjie
authors.initials: J
authors.lastname: Chai
authors.lastname: Menghebat
authors.forename: Wei
authors.initials: W
authors.lastname: Jiao
authors.forename: Deyu
authors.initials: D
authors.lastname: Sun
authors.forename: Bin
authors.initials: B
authors.lastname: Liang
authors.forename: Jincao
authors.initials: J
authors.lastname: Shi
authors.forename: Cheng
authors.initials: C
authors.lastname: Fu
authors.forename: Xiong
authors.initials: X
authors.lastname: Li
authors.forename: Yiding
authors.initials: Y
authors.lastname: Mao
authors.forename: Xiuling
authors.initials: X
authors.lastname: Wang
authors.lastname: Dolikun
authors.lastname: Guliber
authors.forename: Yanchun
authors.initials: Y
authors.lastname: Wang
authors.forename: Fanghua
authors.initials: F
authors.lastname: Gao
authors.forename: Shuhua
authors.initials: S
authors.lastname: Xiao
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015766:Albendazole / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D004444:Echinococcosis, Hepatic / Q000188:drug therapy*; D004655:Emulsions; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D004655:Emulsions; D015766:Albendazole